TOI Stock Overview
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
The Oncology Institute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.20 |
| 52 Week High | US$2.66 |
| 52 Week Low | US$0.33 |
| Beta | 0.69 |
| 1 Month Change | -23.08% |
| 3 Month Change | -42.31% |
| 1 Year Change | 140.00% |
| 3 Year Change | -88.14% |
| 5 Year Change | n/a |
| Change since IPO | -87.63% |
Recent News & Updates
Recent updates
Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%
Mar 21
Is Oncology Institute (NASDAQ:TOI) A Risky Investment?
Mar 05The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company
Nov 10The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit
Aug 09Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings
May 18Companies Like Oncology Institute (NASDAQ:TOI) Are In A Position To Invest In Growth
Mar 16The Oncology Institute: Capitalizing On Clinical Research Contracts
Dec 22Shareholder Returns
| TOI | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.6% | 2.1% | 1.2% |
| 1Y | 140.0% | 3.6% | 24.7% |
Return vs Industry: TOI exceeded the US Healthcare industry which returned 3.6% over the past year.
Return vs Market: TOI exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| TOI volatility | |
|---|---|
| TOI Average Weekly Movement | 11.6% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TOI's share price has been volatile over the past 3 months.
Volatility Over Time: TOI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 800 | Dan Virnich | theoncologyinstitute.com |
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
The Oncology Institute, Inc. Fundamentals Summary
| TOI fundamental statistics | |
|---|---|
| Market cap | US$87.69m |
| Earnings (TTM) | -US$67.88m |
| Revenue (TTM) | US$324.24m |
0.3x
P/S Ratio-1.3x
P/E RatioIs TOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TOI income statement (TTM) | |
|---|---|
| Revenue | US$324.24m |
| Cost of Revenue | US$264.67m |
| Gross Profit | US$59.57m |
| Other Expenses | US$127.45m |
| Earnings | -US$67.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 18.37% |
| Net Profit Margin | -20.93% |
| Debt/Equity Ratio | 152.3% |
How did TOI perform over the long term?
See historical performance and comparison